Phenylephrine Drugs Market Analysis

Phenylephrine Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on the product type, the market is classified into tablets, syrups, eye drops and other product types. The tablets segment dominated the market with revenue of USD 8.1 billion in 2023.

• Phenylephrine tablets are widely available as over the counter (OTC) products, allowing consumers to purchase them without a prescription. The accessibility and convenience of OTC phenylephrine tablets drive consumer demand and market growth.

   

• Moreover, regulatory approvals and guidelines supporting the safety and efficacy of phenylephrine tablets contribute to market growth by boosting consumer confidence and facilitating product sales. Compliance with regulatory requirements ensures the quality and integrity of phenylephrine tablets, enhancing their market acceptance.

   

• In addition, the increasing awareness about the risks associated with pseudoephedrine and the availability of non-sedating alternatives like phenylephrine tablets, there is a growing consumer preference for phenylephrine-based products that propel the growth of the market.

Based on the route of administration, the phenylephrine drugs market is classified into oral, parenteral, other routes of administration. The oral segment dominated the market with market share of 52.5% in 2023.

• The rising consumer preference for oral dosage form due to their ease of administration and convenience. Oral phenylephrine drugs, such as tablets and liquid formulations, offer a simple and familiar route of administration, making them preferred choices for individuals seeking relief from nasal congestion and related symptoms.

   

• Moreover, the oral route of administration is non-invasive, making it suitable for individuals who may prefer to avoid injections or nasal spray. Oral phenylephrine drugs can be taken orally with water or other liquids, eliminating the need for additional devices or equipment for administration.

   

Based on indication, the phenylephrine drugs market is classified into cold, nasal decongestion, allergic reaction, eye disease, and other indications. Cold segment is expected to exhibit 7% CAGR between 2024 - 2032.

• The rise in the prevalence of the common cold affecting millions of individuals worldwide each year increases the demand for drugs such as phenylephrine to treat infectious diseases propel the growth of the market.

   

• Moreover, cold symptoms are more prevalent during certain seasons, such as fall and winter, when cold viruses are more active. During these times, there is typically an increased demand for cold medications, including those containing phenylephrine, to manage symptoms and provide relief to affected individuals.

   

Based on distribution channel, the phenylephrine drugs market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Drug stores & retail pharmacies segment is expected to exhibit 6.9% CAGR between 2024 - 2032.

• Drug stores and retail pharmacies offer convenient access to a wide range of medications, including phenylephrine-based products, in easily accessible locations. Consumers can purchase these medications without the need for a prescription, making it convenient for them to obtain relief from nasal congestion and related symptoms.

   

• Moreover, with the growing trend toward self-medication and self-care, consumers are more inclined to purchase over-the-counter medications directly from drug stores and retail pharmacies. Phenylephrine-based products cater to this trend by offering effective relief from nasal congestion without the need for a prescription.

In 2023, North America secured a substantial market share of 39.7% in the global phenylephrine drugs market and is expected to dominate throughout the forecast period.

• North America experiences a significant burden of respiratory conditions such as the common cold, allergies, sinusitis, and influenza. These conditions often result in nasal congestion and related symptoms, driving the demand for phenylephrine drugs as decongestants.

   

• Regulatory restrictions on pseudoephedrine, which can be misused in the illicit production of methamphetamine, have led to increased use of phenylephrine as an alternative decongestant in North America. These regulatory constraints drive market growth by expanding the market share of phenylephrine drugs.

   

The phenylephrine drugs market in U.S. is expected to exhibit 6.9% CAGR between 2024 - 2032.

• The U.S. government regulates the sale of pseudoephedrine due to its potential use in illicit drug manufacturing. This has led to the popularity of phenylephrine as an alternative decongestant, driving the growth of phenylephrine drugs in the market.

   

• Moreover, the rise in the prevalence of seasonal allergies and respiratory illness in U.S. such as hay fever and the flu. These conditions drive the demand for phenylephrine drugs, as they are commonly used to treat symptoms like nasal congestion.

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.

• The upsurge in technological advancement has played a major role in driving the growth of the market. In addition, the advances in drug formulations and delivery systems may influence the growth of the phenylephrine drugs market in Germany. Innovative products offering improved efficacy or convenience, such as extended-release formulations or combination drugs, can attract consumers and contribute to market expansion.

The India phenylephrine drugs market is expected to grow with a significant CAGR during the forecast period.

• The high prevalence of respiratory disease in India, including common colds, flu, and allergies, particularly during certain seasons. Nasal congestion is a common symptom of these illnesses, driving the demand for phenylephrine drugs to alleviate congestion and related discomfort.

   

• Moreover, rapid urbanization and changing lifestyles in India have led to increased exposure to pollution, allergens, and other environmental factors that can trigger respiratory problems. As more people move to urban areas and adopt sedentary lifestyles, the demand for medications to manage respiratory symptoms, including phenylephrine drugs, is expected to rise.

   

Brazil secured a substantial market share in the global phenylephrine drugs market.

• Brazil's tropical climate contributes to environmental factors such as high humidity and pollen levels, which can exacerbate respiratory issues and nasal congestion. The prevalence of these environmental factors drives the demand for medications like phenylephrine that provide relief from congestion.

   

• Moreover, pharmaceutical companies in Brazil invest in advertising and marketing campaigns to promote over-the-counter medications, including those containing phenylephrine. These efforts increase awareness and drive consumer demand for phenylephrine products.